~~<i id='442C9EF401'><strike id='442C9EF401'><tt id='442C9EF401'><pre id='442C9EF401'></pre></tt></strike></i>~~

Home» comprehensive» hotspot

hotspot

author：comprehensive 2025-10-01 12:25:32 Page View：6

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Canadian wildfire dangers should prompt more proactive mitigation from government: Experts
Next article： Cancer drug shortages should be causing more outrage

explore

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

FILE-TravelersmaketheirwaythroughtheNashvilleInternationalAirport,May25,2023,inNashville,Tenn.Months

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

DarronCummings/APLONDON—AU.K.governmentagencyonTuesdaysaidthatitwon’trecommendEliLilly’sMounjaro—par